ACAD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ACADIA Pharmaceuticals Inc (ACAD) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has shown strong financial growth in its latest quarter and has positive analyst sentiment, the technical indicators suggest a bearish trend, and there are no immediate catalysts or trading signals to support a strong entry point. The stock may be better suited for monitoring until a clearer upward trend or stronger signals emerge.
The technical indicators show a bearish trend with the SMA_200 > SMA_20 > SMA_5. The RSI is neutral at 36.711, and the MACD histogram is positive but contracting. The stock is trading near its support level of 21.213, but there is no clear upward momentum.
Strong financial performance in Q4 2025, with revenue up 9.39% YoY and net income up 90.32% YoY.
Positive analyst sentiment with multiple buy ratings and price targets ranging from $24 to $
Stable Nuplazid sales and a promising pipeline opportunity estimated at $11B.
Bearish technical indicators and a recent price decline of -2.34% in the regular market.
Lack of recent news or event-driven catalysts.
No significant hedge fund, insider, or congress trading activity in recent months.
In Q4 2025, ACADIA Pharmaceuticals reported revenue of $283.99M (up 9.39% YoY), net income of $273.57M (up 90.32% YoY), and EPS of 1.59 (up 84.88% YoY). However, gross margin slightly declined to 90.77% (-0.91% YoY).
Analysts are broadly positive on ACAD, with multiple buy ratings and price targets ranging from $24 to $37. RBC Capital recently lowered its price target to $29 but maintained an Outperform rating, citing seasonal headwinds but favorable sector perceptions. BofA and JPMorgan highlight the stock's strong fundamentals and pipeline potential.
